← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Centre Hospitalier De L'Universite De Montreal (University Of Montreal Hospital)
Montreal, PQ
$13,349,758
Total funding
7
Grants
Funding over time
peak $3.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,349,758 · 7
By mechanism
R01$12,960,779 · 5
R21$247,280 · 1
U10$141,699 · 1
Investigators at Centre Hospitalier De L'Universite De Montreal (University Of Montreal Hospital)
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Interpericyte tunneling nanotubes as new therapeutic targets for neurovascular recovery and vision restoration in glaucoma.$2,674,763
R01 · FY2025 · EY
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$829,283
R01 · FY2025 · AG
Retinal Ganglion Cell Dendrite and Synapse Regeneration in Glaucoma: the Role of Insulin Signaling.$609,416
R01 · FY2023 · EY
Retinal Ganglion Cell Dendrite and Synapse Regeneration in Glaucoma: the Role of Insulin Signaling.$607,276
R01 · FY2020 · EY
Retinal Ganglion Cell Dendrite and Synapse Regeneration in Glaucoma: the Role of Insulin Signaling.$591,134
R01 · FY2022 · EY
Retinal Ganglion Cell Dendrite and Synapse Regeneration in Glaucoma: the Role of Insulin Signaling.$591,133
R01 · FY2021 · EY
Retinal Ganglion Cell Dendrite and Synapse Regeneration in Glaucoma: the Role of Insulin Signaling.$507,148
R01 · FY2024 · EY
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$439,372
R01 · FY2022 · AG
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$438,200
R01 · FY2020 · AG
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$434,974
R01 · FY2018 · AG
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$433,867
R01 · FY2016 · AG
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$433,719
R01 · FY2023 · AG
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$427,996
R01 · FY2024 · AG
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$399,411
R01 · FY2019 · AG
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$395,625
R01 · FY2017 · AG
Immunoregulatory networks and HIV pathogenesis$265,950
R01 · FY2015 · HL
Immunoregulatory networks and HIV pathogenesis$264,600
R01 · FY2014 · HL
Immunoregulatory networks and HIV pathogenesis$257,040
R01 · FY2013 · HL
HB-EGF as a central regulator of pancreatic beta-cell proliferation$221,682
R01 · FY2020 · DK
HB-EGF as a central regulator of pancreatic beta-cell proliferation$221,682
R01 · FY2017 · DK